Ascendis Pharma shares three-year results from Phase 2 PaTH Forward trial

Ascendis Pharmashared 3-year results from the Company’s ongoing Phase 2 PaTH Forward Trial of 57 adults with hypoparathyroidism showing that long-term treatment with TransCon PTH through Week 162 drove bone remodeling into the normal range. Deficiency of parathyroid hormone is associated with low rates of bone remodeling, accumulation of overly mature bone, and higher-than-average bone mineral density that may correspond with poorer overall bone quality compared to that seen in the general population. In contrast, these results suggest that long-term palopegteriparatide treatment promotes attainment of skeletal health parameters in line with those expected with states of parathyroid sufficiency. TransCon PTH is a prodrug of parathyroid hormone, administered once daily, designed to provide continuous exposure to released PTH over the 24-hour dosing period. Lead author Mishaela Rubin, M.D., Associate Professor of Medicine at Columbia University and an expert at the forefront of characterizing the dynamic and structural abnormalities of bone in hypoparathyroidism, shared the results in an oral presentation during ASBMR 2024, the annual meeting of the American Society for Bone & Mineral Research held in Toronto September 27-30.